Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors

Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors

The ABL kinase inhibitor imatinib has been used as front-line therapy for Philadelphia-positive chronic myeloid leukemia. However, a significant proportion of imatinib-treated patients relapse due to occurrence of mutations in the ABL kinase domain. Although inhibitor sensitivity for a set of mutati...

Full description

Bibliographic Details
Main Authors: Swapna Kamasani, Sravani Akula, Sree Kanth Sivan, Vijjulatha Manga, Justus Duyster, Dashavantha Reddy Vudem, Rama Krishna Kancha
Format: Article
Language:English
Published: IOS Press 2017-04-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317701643

Internet

https://doi.org/10.1177/1010428317701643

Similar Items